Fulcrum Therapeutics, Inc. (FULC): Price and Financial Metrics


Fulcrum Therapeutics, Inc. (FULC)

Today's Latest Price: $17.85 USD

0.78 (4.57%)

Updated Jul 2 4:00pm

Add FULC to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

FULC Daily Price Range
FULC 52-Week Price Range

FULC Stock Price Chart Technical Analysis Charts


FULC Price/Volume Stats

Current price $17.85 52-week high $22.96
Prev. close $17.07 52-week low $4.37
Day low $17.32 Volume 49,748
Day high $19.00 Avg. volume 90,719
50-day MA $17.35 Dividend yield N/A
200-day MA $13.51 Market Cap 417.21M

Fulcrum Therapeutics, Inc. (FULC) Company Bio


Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.


FULC Latest News Stream


Event/TimeNews Detail
Loading, please wait...

FULC Latest Social Stream


Loading social stream, please wait...

View Full FULC Social Stream

Latest FULC News From Around the Web

Below are the latest news stories about Fulcrum Therapeutics Inc that investors may wish to consider to help them evaluate FULC as an investment opportunity.

Why This FDA Update Is Crucial for Fulcrum Therapeutics and COVID-19

No summary available.

24/7 Wall street | June 24, 2020

Is Fulcrum Therapeutics (FULC) Stock a Solid Choice Right Now?

Fulcrum Therapeutics (FULC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | June 24, 2020

Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients

Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it received early notification from the U.S. Food and Drug Administration (FDA) that the company may proceed with initiating a Phase 3, randomized, double-blind, placebo-controlled trial of losmapimod in higher risk hospitalized adults with COVID-19. Losmapimod is an orally available selective p38α/β mitogen activated protein kinase (MAPK) inhibitor.

Yahoo | June 24, 2020

Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19 patients

Yahoo | June 24, 2020

Do Hedge Funds Love Fulcrum Therapeutics, Inc. (FULC)?

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 12, 2020

Read More 'FULC' Stories Here

FULC Price Returns

1-mo -6.25%
3-mo 74.83%
6-mo -1.65%
1-year N/A
3-year N/A
5-year N/A
YTD 7.27%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8958 seconds.